Verona Pharma plc
Small-molecule respiratory therapeutics for chronic lung diseases, including ensifentrine for COPD
- Sector
- Biotech
- Headquarters
- London, X0
- Latest Form D
- $200M, Jul 2020
- Total capital
- $245M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $245M
- 2 Form D · last Jul 2020
- 75 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 14
- 7 pending · first 2017
- Rank in peer group#122 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$200M
- Private capital raisedForm D · SEC · 1st filing$44.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#122 · top 8%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Anders UllmanDirectorNamed in SEC Form D filings
- Andrew W. SinclairDirectorNamed in SEC Form D filings
- Claire W. PollExecutive OfficerNamed in SEC Form D filings
- David W. EbsworthDirectorNamed in SEC Form D filings
- David ZaccardelliExecutive Officer, DirectorNamed in SEC Form D filings
- Jan-Anders KarlssonExecutive Officer, DirectorNamed in SEC Form D filings
Show all 16 people
- Kathleen W. RickardExecutive OfficerNamed in SEC Form D filings
- Ken CunninghamDirectorNamed in SEC Form D filings
- Kenneth NewmanExecutive OfficerNamed in SEC Form D filings
- Mahendra W. ShahDirectorNamed in SEC Form D filings
- Mark W. HahnExecutive OfficerNamed in SEC Form D filings
- Martin W. EdwardsDirectorNamed in SEC Form D filings
- Patrick HumphreyDirectorNamed in SEC Form D filings
- Peter SpargoExecutive OfficerNamed in SEC Form D filings
- Rishi W. GuptaDirectorNamed in SEC Form D filings
- Vikas W. SinhaDirectorNamed in SEC Form D filings
What it has protected
USPTO · 14 granted of 21- GrantedFormulation Production ProcessUSPTOUS 12,409,180
- GrantedParticulate CompositionUSPTOUS 12,251,384
- GrantedParticulate CompositionUSPTOUS 12,194,045
Show all 21 patent records
- Formulation Production ProcessSep 9, 2025 · US 12,409,180Granted
- Particulate CompositionMar 18, 2025 · US 12,251,384Granted
- Particulate CompositionJan 14, 2025 · US 12,194,045Granted
- Formulation Production ProcessDec 17, 2024 · US 12,168,011Granted
- New TreatmentSep 19, 2023 · US 11,759,467Granted
- Salt Of A PYRIMIDO[6,1-A]ISOQUINOLIN-4-ONE CompoundNov 8, 2022 · US 11,491,155Granted
- Pharmaceutical Composition Comprising EnsifentrineAug 25, 2022 · Application 17632891Pending
- Pharmaceutical Compositions Comprising RPL554 In HFA-134A For Administration By InhalationDec 9, 2021 · Application 17280452Pending
- Liquid Inhalation Formulation Comprising RPL554Mar 16, 2021 · US 10,945,950Granted
- New TreatmentDec 15, 2020 · US 10,864,213Granted
- New Compound And ProcessJul 14, 2020 · US 10,710,998Granted
- Drug Combination Of PDE3/PDE4 Inhibitor And Muscarinic Receptor AntagonistNov 12, 2019 · US 10,471,063Granted
- Salt Of A PYRIMIDO[6,1-A]ISOQUINOLIN-4-ONE CompoundNov 5, 2019 · US 10,463,665Granted
- Liquid Inhalation Formulation Comprising RPL554May 1, 2018 · US 9,956,171Granted
- Drug CombinationAug 1, 2017 · US 9,717,732Granted
- Drug CombinationJul 11, 2017 · US 9,700,558Granted
- Pharmaceutical Compositions Of Ensifentrine For Chronic Obstructive Pulmonary DiseaseApplication 63550792Pending
- Pharmaceutical Compositions Of Ensifentrine For Chronic Obstructive Pulmonary DiseaseApplication 63550786Pending
- TreatmentApplication 63549608Pending
- TreatmentApplication 63580728Pending
- Liquid Pharmaceutical CompositionApplication 63502977Pending
Related companies, and why
- SeaStar Medical Holding CorpSimilar federal contract value in Biotech · null in contracts
- EvommuneSimilar federal contract value in Biotech · null in contracts
- eGenesisSimilar federal contract value in Biotech · null in contracts
- TRIANGLE THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
- Capstan TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Apnimed, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .